{"filings":[{"id":1222081,"accession_number":"0001193125-26-279428","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-06-23T20:05:31+00:00","items":["8.01"],"status":"ready","headline":"Janux Therapeutics CMO Dr. William Go departs; no impact on clinical timelines","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO William Go, M.D., Ph.D. departed June 23, 2026; company determined termination without Cause under severance plan.","Company initiated search for successor; existing clinical leadership team assumes interim responsibilities.","Departure not due to disagreement with company on operations, policies, or practices.","Transition does not affect development strategy, regulatory plans, or previously disclosed clinical timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027324,"accession_number":"0001193125-26-269387","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-06-12T20:06:06+00:00","items":["5.07"],"status":"ready","headline":"Janux Therapeutics shareholders elect directors, ratify auditor, approve Say-on-Pay at 2026 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Natasha Hernday and Eric Dobmeier elected as Class II directors; Hernday received 42.85M votes for, Dobmeier 46.28M.","Ernst & Young ratified as independent auditor for FY2026 with 53.56M votes for, 113k against.","Advisory vote on named executive officer compensation passed with 42.75M For, 4.57M Against, 46k abstentions.","Total shares outstanding 60.96M; 53.74M shares represented at the meeting (88% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95730,"accession_number":"0001193125-26-211964","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 2026 net loss $24.4M; cash $956.4M; discontinues JANX008, initiates JANX014","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.4M for Q1 2026 vs $23.5M YoY; cash and investments at $956.4M.","Discontinued JANX008 (EGFR-TRACTr) development after Phase 1a; resources redirected.","Initiated clinical evaluation of JANX014 (PSMA-TRACTr); JANX007 combination with darolutamide enrolling.","BMS collaboration milestone triggered $35M payment upon development candidate nomination.","Appointed William Go, M.D., Ph.D. as Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":3733000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95729,"accession_number":"0001193125-26-187641","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux reclassifies director Eric Dobmeier from Class III to Class II to rebalance board classes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On April 28, 2026, Eric Dobmeier resigned as Class III director and immediately reappointed as Class II director.","Change effective to achieve more equal balance among the three director classes on the Board.","Dobmeier's service deemed uninterrupted for vesting, equity awards, and compensation purposes.","Dobmeier continues on the Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109008,"accession_number":"0001193125-26-076627","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports FY2025 net loss $113.6M; cash $966.6M; BMS collaboration with $50M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $966.6M at Dec 31, 2025, down from $1.03B a year ago.","R&D expenses $125.9M for FY2025 vs $68.4M; net loss $113.6M vs $69.0M in 2024.","Entered collaboration with Bristol Myers Squibb for tumor-activated therapeutic; $50M upfront + up to $800M milestones.","Appointed Dr. William Go as CMO; JANX007/008/011 trials continue enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109007,"accession_number":"0001193125-26-019520","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Janux licenses tumor-activated therapeutic to BMS for solid tumors; up to $800M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $15M and near-term milestone $35M; total milestones up to ~$800M.","Janux responsible for preclinical through IND; BMS handles later development and commercialization.","Tiered royalties on global net sales: high-single to low-double digit percentages.","Collaboration validates Janux's TRACTr/TRACIr/ARM platforms for solid tumor oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125466,"accession_number":"0001193125-25-269518","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q3 2025 net loss narrows to $24.3M; cash at $989M; trial enrollment continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3M improved from $28.1M in Q3 2024; R&D expense rose to $34.6M from $18.6M.","Cash, equivalents & short-term investments totaled $989.0M, down from $1.03B at Dec 31, 2024.","Enrollment ongoing in Phase 1 trials for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected Q4 2025.","G&A expense fell to $10.6M vs $17.7M, last year included $9.5M stock-comp modification charge."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":10000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142201,"accession_number":"0001193125-25-209259","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux Therapeutics CSO Byron Robinson departs effective Sept 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Byron Robinson, Ph.D., Chief Strategy Officer, departed Janux effective September 18, 2025.","Company determined termination without 'Cause' under Change in Control and Severance Benefit Plan.","No successor or interim CSO announced; departure of named executive officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142200,"accession_number":"0000950170-25-105010","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q2 net loss $33.9M; cash $996M; Merck milestone $10M triggered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $996.0M at June 30, 2025, vs $1.03B at Dec 31, 2024.","R&D expenses $34.7M (Q2 2025) vs $14.9M (Q2 2024); net loss $33.9M vs $6.0M.","First patient dosed in lead Merck collaboration program triggered $10M milestone payment.","Enrollment ongoing for JANX007 (mCRPC) and JANX008 (solid tumors); data updates expected H2 2025.","R&D Day highlighted preclinical PSMA-TRACIr, TROP2-TRACTr, and CD19-ARM programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160206,"accession_number":"0000950170-25-086284","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Janux Therapeutics shareholders elect three Class I directors, ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.","Ernst & Young ratified as auditor for FY2025: 56.15M for, 27K against.","Advisory vote on executive compensation approved: 53.2M for, 1.15M against.","Advisory vote favors 1-year frequency for future say-on-pay votes: 54.0M for 1 year.","59.2M shares outstanding, 56.2M present at meeting; broker non-votes of 1.87M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160205,"accession_number":"0000950170-25-066969","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).","Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.","R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.","Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.","Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178504,"accession_number":"0000950170-25-029165","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics reports FY2024 net loss $69M, cash $1.03B, positive JANX007 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $1.03B at year-end 2024, up from $344M in 2023, largely from $402.5M December offering.","Net loss $69.0M for FY2024 ($20.2M Q4), vs $58.3M prior year; R&D spend $68.4M.","JANX007 PSMA-TRACTr Phase 1: 100% PSA50, 63% PSA90, 50% ORR (4/8), well-tolerated safety; data cutoff Nov 15, 2024.","JANX008 EGFR TRACTr Phase 1 enrollment ongoing; data update and R&D Day planned for 2025.","Zachariah McIver promoted to Chief Medical Officer; he previously served as Amgen's Executive Medical Director."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":10588000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195175,"accession_number":"0001193125-24-271578","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Janux Therapeutics prices $350M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,317,460 shares at $63.00/share and pre-funded warrants for 238,095 shares at $62.999","Gross proceeds expected ~$350M before expenses; funds to advance clinical pipeline and for general purposes","Underwriters granted 30-day option to purchase up to additional 833,333 shares","Offering expected to close Dec 6, 2024; joint book-runners: BofA, TD Cowen, Stifel, Cantor, William Blair"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195174,"accession_number":"0000950170-24-132302","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Janux reports positive interim JANX007 data; selects doses for Phase 1b expansion in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of 16 patients achieved PSA50 declines; 63% PSA90; 31% PSA99 declines.","75% maintained PSA50 and 50% maintained PSA90 at ≥12 weeks.","50% ORR (4/8 RECIST-evaluable patients) with confirmed/unconfirmed partial responses.","CRS and TRAEs primarily cycle 1, grade 1-2; MTD not yet reached.","Two once-weekly step dose regimens identified for Phase 1b in pre-PLUVICTO 2L/3L patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195173,"accession_number":"0000950170-24-122279","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.","Net loss $28.1M for Q3 2024 vs $11.6M in Q3 2023; R&D expenses $18.6M vs $11.9M.","G&A expenses $17.7M for Q3 2024 including $9.5M stock-based compensation from equity modifications.","Enrollment continues for JANX007 (PSMA-TRACTr) in mCRPC and JANX008 (EGFR-TRACTr) in solid tumors.","Update on JANX007 data and expansion cohort doses anticipated in 2024; JANX008 update in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":10588000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211443,"accession_number":"0000950170-24-092830","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q2 2024 net loss $6.0M; cash $646.3M; receives $7.5M Merck milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M vs $17.5M in Q2 2023; improvement driven by $7.5M milestone payment from Merck.","Cash and investments $646.3M at June 30, 2024, up from $344.0M at Dec 31, 2023.","R&D expense flat at $14.9M; G&A expense $7.8M vs $6.9M in prior year.","Enrollment ongoing for JANX007 (PSMA) and JANX008 (EGFR) trials; JANX007 data update expected 2H 2024.","Appointed Eric Dobmeier and Natasha Hernday to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":10149000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211442,"accession_number":"0000950170-24-085321","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-07-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Janux Therapeutics board reshuffles: Lichter resigns, Barrett becomes Chair, Hernday and Dobmeier appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jay Lichter, Ph.D. resigned from the board effective July 19, not due to any disagreement.","Ron Barrett, Ph.D. appointed as Chairperson of the Board.","Natasha Hernday (former Seagen CBO) and Eric Dobmeier (former Chinook CEO) join as Class II and III directors.","New directors received standard equity grants: options for 16,700 shares and RSUs for 5,000 shares each.","Hernday led Seagen's $43B Pfizer acquisition; Dobmeier led Chinook's $3.5B Novartis sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230086,"accession_number":"0000950170-24-079059","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Janux shareholders elect three Class III directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors elected: Vickie Capps, Jay Lichter, and Jake Simson, each with >41 million votes for.","Ernst & Young ratified as independent auditor for FY2024 with 49,801,743 votes for, 1,682 against.","51,850,667 shares outstanding as of record date April 29, 2024; broker non-votes reported for director election.","All proposals passed; no other business items were voted on at the 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230085,"accession_number":"0000950170-24-054950","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics Q1 2024: Cash $651.8M; net loss $14.8M; trials ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $651.8M as of March 31, 2024, up from $344.0M at Dec 31, 2023.","Net loss $14.8M for Q1 2024, improved from $17.5M in Q1 2023; R&D expenses $14.1M vs $15.9M.","Enrollment ongoing in Phase 1 trials for JANX007 (PSMA-TRACTr in mCRPC) and JANX008 (EGFR-TRACTr in solid tumors).","JANX007 data update and expansion cohort doses anticipated in 2H 2024; JANX008 data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":1252000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248523,"accession_number":"0000950170-24-028647","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports $344M year-end cash; Q4 net loss $11.8M; positive Phase 1 JANX007/JANX008 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-end cash & investments $344M; net loss $58.3M for FY 2023 vs $63.1M in 2022.","Raised ~$320.2M net in March 2024 underwritten offering to fund clinical pipeline.","Phase 1 JANX007 in mCRPC: 83% PSA50 at first step dose ≥0.2mg; no CRS > Grade 2.","Phase 1 JANX008: NSCLC subject achieved RECIST PR with 100% target lesion reduction, no CRS.","Co-founder Dr. Tommy DiRaimondo promoted to CSO; JANX007 update expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248522,"accession_number":"0000950170-24-023257","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.","Gross proceeds ~$296.5M, up from initial $175M offering; underwriters have 30-day option for 956,450 shares.","Proceeds to fund clinical pipeline development and general corporate purposes; close expected March 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248521,"accession_number":"0000950170-24-022266","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Janux Therapeutics suspends ATM equity offering program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered written notice to BofA on Feb 28, 2024 suspending the ATM prospectus supplement.","No further sales of common stock under the Sales Agreement until a new prospectus supplement is filed.","Sales Agreement remains in full force and effect; suspension does not terminate it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248520,"accession_number":"0000950170-24-021425","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Janux reports positive interim Phase 1a data for PSMA-TRACTr and EGFR-TRACTr; cash at $338.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At JANX007 starting dose ≥0.2 mg, 6/6 (100%) achieved PSA30 and 5/6 (83%) PSA50; one PSA90 observed.","CRS for JANX007 only Grade 1/2 and transient; doses up to 3 mg with no MTD reached.","JANX008: One NSCLC subject with confirmed PR (100% lung target reduction, liver mets eliminated); no CRS or TRAEs.","11 heavily pre-treated subjects enrolled across four tumor types in JANX008; no SAEs or DLTs.","Preliminary cash, equivalents, and short-term investments ~$338.2M as of Jan 31, 2024 (incl. $0.8M restricted)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248519,"accession_number":"0000950170-24-020183","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.","JANX008: NSCLC subject achieved confirmed PR with 100% target lung lesion reduction and elimination of liver metastasis; no CRS or TRAEs.","JANX008: No Grade 2+ CRS, no treatment-related SAEs or DLTs across 11 heavily pretreated patients across 4 tumor types.","Janux hosting virtual investor event today at 4:30 PM ET to discuss data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266027,"accession_number":"0000950170-23-060238","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics Q3 net loss narrows to $11.6M; cash $349.7M supports operations through 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.6M vs $16.7M YoY; R&D expenses $11.9M, G&A $6.4M.","Cash and short-term investments $349.7M, up from $327.0M at year-end 2022, expected to fund operations through 2027.","Enrollment ongoing for JANX007 (PSMA-TRACTr) in prostate cancer and JANX008 (EGFR-TRACTr) in solid tumors; update expected in 2024.","IND-enabling studies completed for JANX009 (PD-L1xCD28 TRACIr); TROP2-TRACTr candidate identified."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":5622000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283258,"accession_number":"0000950170-23-039843","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Janux Q2 net loss $17.5M; cash $303.3M; Nasdaq compliance regained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.5M for Q2 2023 vs. $16.9M in Q2 2022; R&D expense $14.9M, G&A $6.9M.","Cash, cash equivalents & short-term investments of $303.3M at June 30, 2023; July offering raised ~$60M gross.","PSMA-TRACTr JANX007 Phase 1 data showed meaningful PSA drops with manageable safety/CRS profile.","Nasdaq compliance regained after Ron Barrett, Ph.D. became independent director; matter closed.","Appointed Dr. Zachariah McIver as VP, Clinical Development; he brings >15 years bispecific experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":3105000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283257,"accession_number":"0001193125-23-188867","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Janux Therapeutics prices $60M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 4,153,717 shares at $12.46/share and pre-funded warrants for 583,483 shares at $12.459 each.","Gross proceeds ~$60M before underwriting discounts and commissions.","Offering expected to close on or about July 19, 2023.","BofA Securities acting as sole bookrunner for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283256,"accession_number":"0001193125-23-187702","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.","JANX007 Phase 1a: 4 of 5 patients at flat doses (100-300µg) achieved PSA reductions of 31-67%.","No dose-limiting toxicities; CRS Grade 1-2 only in patients with PSA reductions; no Grade 3 CRS.","PK shows prolonged TRACTr exposure and lack of TCE accumulation, consistent with tumor activation.","Development moving into step-dosing and dose optimization to enhance efficacy with manageable safety."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302679,"accession_number":"0000950170-23-029662","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux Therapeutics CMO Wayne Godfrey resigns; Chief Strategy Officer Byron Robinson interim lead","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Wayne Godfrey resigns as CMO effective July 5, 2023 for personal reasons; no disagreement with company.","Byron Robinson, Ph.D., Chief Strategy Officer, appointed interim head of clinical activities and team.","Robinson assumes leadership immediately; company emphasizes experienced clinical team remains in place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302678,"accession_number":"0000950170-23-028982","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Janux loses majority-independent board after director exit; Nasdaq grants cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Independent director Peter Thompson did not stand for re-election, reducing independent directors to 4 out of 9 total.","Nasdaq notified company of non-compliance with majority independence rule (5605(b)(1)); cure period extends to June 14, 2024.","Board evaluating options to regain compliance within cure period.","At annual meeting, stockholders elected Sheila Gujrathi and Alana McNulty as Class II directors.","Ratified Ernst & Young as independent auditor for FY 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302677,"accession_number":"0000950170-23-019856","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Janux Therapeutics enters into $150M ATM equity offering agreement with BofA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $150M in common stock may be sold at the company's discretion through BofA as sales agent or principal.","BofA will receive up to 3% commission on gross proceeds; company also reimburses certain legal fees.","Sales may occur via negotiated transactions, block trades, or at-the-market on Nasdaq.","The offering is under an existing S-3 registration statement; no obligation to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302676,"accession_number":"0000950170-23-019641","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.","R&D expenses $15.9M (up from $10.2M); G&A $6.5M (up from $4.9M).","First patient enrolled in EGFR-TRACTr (JANX008) Phase 1 for solid tumors.","Interim clinical update for PSMA-TRACTr (JANX007) expected in 2H 2023.","PD-L1xCD28 TRACIr (JANX009) IND on track for submission in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":2048000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322322,"accession_number":"0000950170-23-011433","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Peter Thompson to not stand for re-election at Janux 2023 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Thompson, M.D., informed Janux he will not stand for re-election to the Board at the 2023 annual meeting due to competing commitments.","Dr. Thompson's decision is not the result of any disagreement with the Company on operations, policies, or practices.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322321,"accession_number":"0000950170-23-007286","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics posts 2022 net loss of $63.1M; cash at $327M; JANX007 update expected 2H 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $63.1M for FY2022, vs $32.7M in FY2021; R&D expenses doubled to $53.4M.","Cash and short-term investments $327.0M at Dec 31, 2022, down from $375.0M at Dec 31, 2021.","FDA clearance for JANX008 (EGFR-TRACTr) IND; JANX009 IND submission on track 2023.","Interim clinical update from JANX007 (PSMA-TRACTr) Phase 1 trial expected in H2 2023.","Janux states SVB exposure is immaterial and will not impact short- or long-term objectives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340360,"accession_number":"0000950170-22-024472","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q3 net loss $16.7M; first patient dosed in JANX007 Phase 1 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss of $16.7M vs $10.8M prior year; R&D spend $13.7M (up from $8.4M).","Cash and short-term investments $338.8M at Sep 30, 2022, down from $375.0M at Dec 31, 2021.","First patient dosed with JANX007 in Phase 1 trial for prostate cancer; interim data expected 2H 2023.","IND for EGFR-TRACTr (JANX008) on track for 2H 2022; PD-L1xCD28 TRACIr (JANX009) IND planned for 2023.","Strengthened management with new HR head and board addition Winston Kung."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":5767000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357617,"accession_number":"0000950170-22-018774","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Janux appoints Winston Kung to board; Stefan Heller resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Winston Kung appointed as Class I director, term expiring at 2025 annual meeting, effective Sept 21, 2022.","Stefan Heller resigned from board effective same day; not due to any disagreement with the company.","Kung receives $40k annual cash retainer (board) + $4k (committee) and stock options: 30k shares (3-yr vest) and 9,375 shares (1-yr vest).","Kung is CFO/COO at PMV Pharma; prior VP Business Development at Celgene and roles at Citigroup and Amgen.","Changes effective immediately per press release dated September 22, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357616,"accession_number":"0000950170-22-016068","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics reports Q2 net loss of $16.9M; IND cleared for lead candidate JANX007","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $16.9M vs $6.2M in Q2 2021; R&D expenses rose to $14.1M from $4.7M.","Cash and short-term investments $354.3M (Dec 31, 2021: $375.0M).","FDA cleared IND for JANX007 (PSMA-TRACTr) for mCRPC; Phase 1 trial expected 2H 2022.","IND submission for JANX008 (EGFR-TRACTr) on track for 2H 2022; TROP2-TRACTr IND planned for 2023.","First TRACIr candidate (PD-L1xCD28) IND-enabling studies ongoing; IND submission expected 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376223,"accession_number":"0000950170-22-011646","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Janux Therapeutics stockholders elect three Class I directors, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Campbell, Ron Barrett, and Stefan Heller elected as Class I directors with 33.9M, 34.7M, and 33.9M votes for, respectively.","Ernst & Young LLP ratified as independent auditor for FY2022 with 37.85M votes for, 3 against, 244 abstentions.","Broker non-votes of 2,998,529 on all director elections; none on auditor ratification.","Total outstanding shares as of record date April 18, 2022: 41,629,367."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376222,"accession_number":"0000950170-22-008972","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Q1 net loss $13.4M; cash $361.2M; IND filed for JANX007","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.4M for Q1 2022 vs. $2.3M in Q1 2021; R&D spend $10.2M, G&A $4.9M.","Cash & investments $361.2M at March 31, 2022, down from $375.0M at Dec 31, 2021.","IND submitted for PSMA-TRACTr (JANX007); IND for EGFR-TRACTr (JANX008) expected 2H 2022.","Merck nominated a second target under the 2020 collaboration agreement in May 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":1589000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376221,"accession_number":"0000950170-22-006779","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Management presented two posters at PEGS Boston on May 2-5, 2022.","JANX007 is a PSMA-targeted TRACTr for prostate cancer; JANX008 is EGFR-targeted for solid tumors.","Data is preclinical; no clinical results or financial guidance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394576,"accession_number":"0000950170-22-004161","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports FY2021 net loss $32.7M; cash $375M; IND filings for two TRACTr programs on track for 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.","Net loss $13.4M for Q4 2021 and $32.7M for FY2021; R&D expense $26.2M (FY2021).","PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.","Nominated first TRACIr candidate, a PD-L1xCD28 costimulatory bispecific; IND planned for 2023.","Appointed Byron Robinson, Ph.D., J.D., as Chief Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413204,"accession_number":"0000950170-21-003727","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux reports Q3 net loss of $10.8M, cash $387.5M; IND filings on track for 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $387.5M at Sept 30, 2021, up from $7.8M at Dec 31, 2020.","R&D expenses $8.4M (vs $0.8M in Q3 2020); G&A $3.6M (vs $0.4M).","PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.","TRACIr costimulatory bispecific candidate selection planned in 2022.","Board strengthened with appointments of Ron Barrett (Ph.D.) and Alana McNulty."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":2021000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413203,"accession_number":"0000950170-21-001977","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Janux Therapeutics enters 126-month lease for ~47,300 sq ft lab/office space in San Diego","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 47,300 sq ft at 10955 Vista Sorrento Pkwy, San Diego; commencement July 1, 2022.","Base rent $271,952/month first year, with 6 months abated; 3% annual escalations thereafter.","Tenant improvement allowance of ~$10.64 million from landlord.","Letter of credit requirement of $815,856, reducible by 50% after 54 months.","Term of 126 months; space for office, lab, vivarium, and R&D use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431803,"accession_number":"0000950170-21-001745","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux Therapeutics appoints Ronald Barrett and Alana McNulty as directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ronald Barrett, Ph.D. appointed as Class I director with term expiring at 2022 annual meeting.","Alana McNulty appointed as Class II director with term expiring at 2023 annual meeting.","Each receives $40,000 annual cash retainer and option to purchase 30,000 shares vesting over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431802,"accession_number":"0000950170-21-001576","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Janux enters 13-month lease for San Diego office space at ~$22k/month","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leased 7,432 sq ft at 10590 West Ocean Air Dr, San Diego, CA.","Monthly base rent ~$21,924 (first year) with second month abated; rises to $22,890 in month 13.","Lease term 13 months, commencement expected Oct 1, 2021.","Premises will be used for general office purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431801,"accession_number":"0000950170-21-001172","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Janux Therapeutics Q2 net loss $6.2M; cash $394.2M post $222.9M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed $222.9M IPO in June and $125.0M Series B in April, total $347.9M in quarter.","Cash and short-term investments of $394.2M at June 30, 2021 vs $7.8M at Dec 31, 2020.","Q2 net loss of $6.2M, compared to $2.5M in same period 2020; R&D expense $4.7M.","On track to submit at least two INDs by end of 2022 for lead TRACTr programs.","Appointed Shahram Salek-Ardakani as CSO and Wayne Godfrey as CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":862000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431800,"accession_number":"0001193125-21-217455","cik":1817713,"company_name":"Janux Therapeutics, Inc.","ticker":"JANX","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Janux Therapeutics increases CEO base salary to $500k, bonus target to 50%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO David Campbell's annual base salary increased from $424,408 to $500,000 effective July 15, 2021.","Annual target performance bonus percentage increased from 40% to 50%, retroactive to beginning of 2021.","Changes approved by Board of Directors upon Compensation Committee recommendation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":890676492.4355956,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}